The binding of tritiated ~-endorphin (3H-~-EP) to brain homogenates is described. This had been difficult to achieve due to the lack of availability of 3H-~-EP and to technical difficulties associated with high non-specific binding of ~-EP. We now report that 3H-~-EP binding is saturable, stereospecific, has high affinity and is inhibited by sodium. Its dissociation rate is ten-fold longer than that of naloxone. Its regional distribution exhibits interesting differences from naloxone and enkephalin binding. ACTHt.24 appears to displace it more effectively than it displaces 3H-naloxone. The results are discussed in terms of multiple transmitter systems and the multiple opiate receptor hypothesis.
Introduction
While the endogenous opioid, ~-endorphin (~-EP) was first discovered in the pituitary (Li and Chung, 1976; Bradley et al., 1976) , it is also present within an anatomically distinct neuronal system in mammalian brain. We and others (Watson et al., 1978; Bloom et al., 1978) have shown to existence of ~-EP and its precursors in a well-defined hypothalamic cell group which projects to a number of limbic and midbrain structures. This system is independent of the pituitary ~-EP system, and is readily distinguished from enkephalin pathways (Watson et al., 1978) . Interestingly, the synthetic machinery characteristic of pituitary ~-EP --including the 31K prescursor #Address all correspondence to H. Akil, Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109, U.S.A. described by Mains et al. (1977) --appears to exist within the brain. This conclusion is based primarily on immunohistochemical evidence demonstrating ~-LPH, ACTH and a number ofothex 3iK fragments (Watson et al., 1978) within these ~-EP-containing neurons.
~-EP is known to exhibit opiate-like properties both in vitro (Cox et al., 1976) and in vivo (Loh et al., 1976) . However, in pharmacological doses, it also produces effects which differ, in part, from those of morphine. These include the induction of limbic seizures and rigidity at subanalgesic doses (Bloom et al., 1976) . While 3H-enkephalin binding had been studied and characterized, we know little about the specific properties of ~-EP binding. 3H-~:EP has not been commercially available to date, preventing direct studies of its receptor interactions. Yet, the unique anatomical and biosynthetic properties of the brain ~-EP system, and the distinct pharmacological pro-perties of ~-EP warrant a closer examination of its interaction with a brain receptor. Whether such a receptor would prove to be identical or in some way discernable from the classical 'opiate receptor' (Martin et al., 1976) would shed light on the function of/3-EP and on the hypothesis of multiple opiate receptors. In this paper, we describe 3H-/3-EP binding to rat brain membranes, including a characterization of 'opiate properties', a mapping of regional distribution and interaction with ACTH --another 31K product.
solubilized and counted. The coating of filters with BSA/polylysine (5 ml of 0.01% polylysine/0.4% BSA) is critical for detecting saturable binding. Without coating, over 50% of 3H-~-EP binds non~pecifically to the filters. Both techniques yield similar results, although the ratio of displaceable saturable counts to the total counts is better with filtration (about 60--80% at 3 nM) than it is with centrifugation (30--50% at 3 nM). In both techniques, the standard error of the replicates is approximately 1%.
Materials and methods
Tritium-labelled /~h-EP was synthesized according to a previously described procedure (Houghten and Li, 1978) , achieving a specific activity of 50 Ci/mmole. The binding assay is descibed in greater detail elsewhere (Hewlett, Akil, Barchas and Li, in preparation). Briefly, whole rat brains minus cerebella are homogenized in 12 vol of Tris HC1 (pH 7.8 at 25°C) and centrifuged at 35000 × g for 30 min. The pellet is then resuspended in buffer and allowed to incubate for 1 h at room temperature. It is then recentrifuged and suspended in the same volume. 3H-~-EP (0.025 ml)at varying concentrations is incubated with 0.2 ml of this membrane preparation in the presence or absence of unlabeUed/3-EP (in 0.025 ml). To determine saturable and non-specific binding, a 2 pM concentration of unlabelled ~-EP is routinely used. Incubation is carried out for 2--3 hours at 0°C. Because of ~-EP's great propensity to adhere to surfaces, separation of bound from free aH-/3-EP is extremely critical and technically difficult. Good separation is achieved in one of two ways: the first involves centrifugation in a Sorvall centrifuge swing bucket rotor (HS4) at 7000 rpm for 20 min. The supernatant is then aspirated, the pellet resuspended in standard buffer and transferred to a vial for liquid scintillation counting. The second separation procedure employs rapid filtration and washing on precoated GF/B Whatman filters, which are then 65 nM. The tissue was incubated at 0°C for 150 min, and bound ~-EP was separated by filtration. Scatchard analysis demonstrates a curvilinear plot which can be resolved into two components, with two distinct affinities and capacities (KD, = 1.0 X 10 -9 M; KD: = 16.7 × 10 -9 M). Similar results are obtained by centrifugation. Displacement curves with unlabelled ~-EP and binding with varying concentrations of labelled material yield similar estimates of affinity and capacity of binding. The total binding capacity in whole brain is estimated at 6.8 pmoles/g of tissue in the illustrated experiment (and has ranged between 6.8 and 13.7 pmoles/g in other experiments) --significantly lower than what is routinely obtained with 3H-naloxone binding in the same preparation. Whether this discrepancy is entirely due to breakdown or to a true difference in receptor number remains to be determined.
Results

Characterization
In three separate studies, we examined the time course of 3H-~-EP binding (table 1). The labelled peptide was incubated in the presence or absence of 2 ~M unlabelled ~-EP for various time periods ranging from 1 min to 24 h. The results indicate that at 0°C equilibrium is reached at 2 h and remains relatively constant for 24 h. The slight decline seen in some preparations at later time points is probably due to some enzymatic breakdown of 3H-~-EP by under identical conditions. After equilibrium was achieved, dissociation was brought about by adding a thousand-fold concentration of unlabeled ligand and filtering at various time points (h) thereafter (abscissa). The curve with filled circles represent the 3H-~-EP results. The unmarked line represents 3H-naloxone dissociation (an equal number of points was studied with 3H-naloxone but those can only be visualized with a different scale, due to the big difference in time course). Incubation at 0°C; ~-EP tl/2 = 90 rain; naloxone t% = 8.5 rain. Ordinate: % control.
the membrane preparation. The best ratio of specific/total DPM is, in fact, achieved at 30 minutes, rather than at equilibrium. The rate of dissociation of 3Ha6-EP from the binding site was estimated by displacing the labelled compound with a high concentration of unlabelled ~-EP ( fig. 2 ). Samples conraining 2 nM 3H-~-EP were allowed to incubate to equilibrium for 2 h, at which point estimates of total and non~pecific binding were obtained. Unlabelled ~-EP at a thousandfold higher concentration (2 #M) were then added. The samples were filtered at several time points thereafter (1 rain to 3 h), with appropriate controls. A plot of log percent specific binding versus time yielded an estimate of tl/2 = 90.33 + 5 min, which is significantly longer than the tl/2 for naloxone under identical conditions (tl/2 = 9 rain) ( fig. 2) .
At higher temperatures, 3H-~-EP binding is decreased rather than enhanced, also pointirtg to enzymatic breakdown of the opioid. While equilibrium at 25°C is achieved more rapidly, the number of specific DPM's bound at 25°C is only 30% of specific binding at 0°C when the incubation is allowed to proceed for 2 h. No specific binding could be seen at 37°C with 2 h incubations.
The effect of tissue concentration on specific binding was examined in two separate studies. Brain homogenates were resuspended in 6, 12, 24 or 36 vol of buffer and tested in the binding assay. The results showed a linear relation between tissue concentration and specific binding, such that binding doubled as the tissue concentration was doubled.
The opiate nature of this binding was investigated in a number of studies. The ability of naloxone, levorphanol, dextrorphan, leucine enkephalin (Leu-E) and methionine enkephalin to displace 3 nM of 3H-~-EP was studied both in whole brain and in brain parts. In all cases, 1 pM of the opiate agonists or antagonists produced between 90 and 100% displacement of saturable ~-EP binding. Dextrorphan, on the other hand, used at the same concentration, left this binding unaltered. These results suggest that the majority of 3H-~-EP is binding to the stereospecific opiate receptor.
The relative potencies of ~-EP and Leu-E are quite different depending on whether they are competing against 3H-Leu-E or 3H-fl-EP. While ~-EP is 13-fold more potent than Leu-E in displacing 3H-~-EP (~-EP ICs0 = 3.5 X 10 -9 M; Leu-E ICs0 = 45 × 10 -9 M), it is half as potent as Leu-E in displacing 3H-Leu E binding (~-EP ICs0 = 20.5 × 10 -9 M; Leu E IC = 9 × 10 -9 M).
Another characteristic of opiate binding is the 'sodium effect'. As an opiate agonist, ~-EP binding would be expected to decrease in the presence of sodium (Pert and Snyder, 1974; Simon et al., 1973 Simon et al., , 1975 . In fact, 100 mM NaC1 produces a total inhibition of all specific binding of 4nM 3H-~-EP. Ten mM NaC1 resulted in 57% inhibition of binding.
In order to study the regional distribution of 3H-~-EP binding, 18 rats were sacrified and iting the highest binding and cerebellum exhibiting little or no specific binding. The rank order of the regions is roughly similar to what we commonly see with binding of other opiates (cf. table 2, Pert and Snyder, 1973) . However, there are also interesting differences --such as the relatively high binding of ~-EP in hippocampus --a result not obtained with either 3H-naloxone or 3H-enkephalin. While the unique profile may be due to differential breakdown, our experiments suggest that under our conditions, breakdown of 3H-~-EP is minimized.
A CTH interactions
centration of labelled ligands was computed, and the data were transformed for Scatchard plot analysis. Fig. 3a demonstrates that throughout the range of labelled concentrations ACTH,.24 produced a dose dependent inhibition of both 3H-naloxone and 3H-~-EP. However, it consistently produced higher inhibition against 3H-/3-EP. Scatchard analyses of the results showed that all concentration of ACTH,.24 inhibited both high and low affinity components of 3H-~-EP binding ( fig. 3b) . However, ACTHI.24, even at concentrations up to 50 pM inhibited primarily the high affinity but not the low affinity component of 3H-naloxone binding ( fig. 3c ).
Since /3-EP is synthesized from a common precursor molecule containing the structure of ACTH1.39, ~-MSH and a number of related peptides, and since Terenius et al. (1975) had demonstrated some interaction of ACTHrelated peptides with the opiate receptor, we tested for possible interactions between 31K-related substances and 3H-~-EP. ~-MSH, /~-MSH, ACTH,9, and modified ACTH4.9 (Org 2766), and DTTE were ineffective at inhibiting 3H-/~-EP binding at concentrations of up to 10 pM. On the other hand, ACTH1.24 exhibited dose dependent inhibition of 3H-~-EP. The ICs0 for ACTHI.24 is 12 pM, obviously significantly higher than ICs0's of opiate peptides or alkaloids.
Nonetheless, the interaction appeared unique to ACTHI.24. It was therefore of interest to determine whether ACTH would displace all opiate binding equally, or whether it would display closer interaction with /3-EP. Table 3 shows that ACTH:.24 appears to displace 3H-/~-EP somewhat more effectively than it did 3H-naloxone or 3H-Met-enkephalin. Therefore, we undertook a more thorough comparison of ACTH1.24 effect on aH-/3-EP and 3H-naloxone binding. Full concentration curves for 3H-~-EP and 3H-naloxone were carried out under four conditions: in the absence of any ACTH~.24, or in the presence of 1 pM, 10 /~M and 50 pM ACTH~.24. Inhibition by each concentration of ACTH,.24 at each con-
Discussion
Thus, 3H-~-EP exhibits high affinity saturable binding to rat brain membranes. This binding bears striking similarities to the 'opiate receptor' in that it is displaced stereospecifically by opiate alkaloids and is sensitive to sodium. Interestingly, Hazum et al. (1979) have recently characterized the binding of iodinated [D-Ala2]~-EP to brain membranes. They have noted that the binding of this peptide is not inhibited by 100 mM sodium chloride. The contrast between the two findings appears to be due to the D-Ala substitution, since in our hand both 3H-/~-EP and '2sI-~-EP are highly sensitive to sodium (Akil and Lin, in preparation) . This suggests that the substitution of glycine by D-Alanine brings about changes in the way the ~-EP analogue interacts with the opiate receptor.
The present results suggest that the two classes of endogenous opioid ligands identified to date --the enkephalins and fl-EP --are recognized by membrane macromolecules which share a common structural unit, leading to a great deal of 'cross reactivity'. It is possible that the specificity of the interactions between opiate receptors and endogenous opiates resides primarily in the anatomical circuitry, or in post-synaptic events. Nonetheless, the notion of 'multiple opiate receptors' is given partial support by the findings that ~-EP and enkephalin exhibit very different relative potencies depending on whether they are competing against 3H-enkephalin or 3H-fl-EP. The differential regional distribution in the binding of 3H-fi-EP and 3H-naloxone also points to a partial separation of subclasses of opiate receptors.
The finding that ACTH1.24 interacts at micromolar concentration with opiate receptors is consistent with the previous report of Terenius et al. (1975) . The present is an extension showing that ACTHI.24 discriminates between 3H-fi-EP and 3H-naloxone, inhibiting both high and low affinity binding components of the former and only the high affinity component of the latter. This is consistent with the notion that ACTH and ~-EP are more closely related, due to their common biosynthetic origin. However, the physiological significance of this interaction is difficult to ascertain, since high concentrations are required for the competition.
~-EP appears to dissociate extremely slowly from its binding site, a finding which is congruent with its high potency and long time course upon in vivo administration. Such slow dissociation has important implications for considering its mode of action in the brain. Since classical neurotransmitters are thought to produce rapid and short-lived effects on the postsynaptic neurons, a longer-acting endogenous ligand could be construed as serving significantly different neuromodulatory functions.
